Galapagos forms research alliance with Merck
Galapagos will be responsible for the discovery and preclinical development of new small molecule candidate drugs based on novel Galapagos targets. Merck will have the exclusive option to
Voro Therapeutics and Alloy Therapeutics have formed a strategic research partnership to develop tumour-selective, next-generation masked T-cell engager (TCE) therapeutics.